Related Experiment Videos
High-risk AML evidenced by a monoclonal antibody
S Avnstrøm1, E Ralfkiaer, N E Hansen
1Finsen Institute, Department of Medicine, Gentofte Hospital, Copenhagen, Denmark.
European Journal of Haematology
|August 1, 1988
Abstract:
A monoclonal antibody has been raised against a surface membrane antigen present on leukemic myeloblasts. In 52 consecutive patients with acute myeloid leukemia treated in a standardized fashion with intensive chemotherapy the immunologic subclass with respect to this antigen was correlated to the clinical outcome. We found the expression of this antigen to predict a poor prognosis, when measured as survival of CR-patients and as survival after 1st relapse.